Evotec SE (MIL:1EVT)
€ 8.345 0 (0%) Market Cap: 1.52 Bil Enterprise Value: 1.61 Bil PE Ratio: 0 PB Ratio: 1.56 GF Score: 54/100

Evotec SE and Sernova Corp to Discuss Exclusive Strategic Partnership M&A Call Transcript

May 17, 2022 / 12:30PM GMT
Operator

Greetings, and welcome to the Sernova and Evotec Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Dr. Philip Toleikis. Thank you, Philip. You may begin.

Philip M. Toleikis
Sernova Corp. - President, CEO & Director

Thank you very much. Welcome, everyone in North America, and good morning, and welcome, everyone in Germany and the rest of Europe, and good afternoon. This is going to be a discussion about the partnership and licensing option agreement for iPSC-based beta cell replacement therapy for insulin-dependent diabetes. And as CEO of Sernova, I am extremely excited to have been working with the team at Evotec, and we see this as a transformational agreement between Sernova and Evotec moving both companies forward.

Next slide, please. Please be aware and read the Sernova forward-looking statements. And also, please be aware of the Evotec forward-looking statements.

So with respect to the partnership highlights and terms, Sernova has

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot